XBiotech (NASDAQ:XBIT) Announces Quarterly Earnings Results

XBiotech (NASDAQ:XBIT) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.34) EPS for the quarter, Zacks reports.

XBiotech Price Performance

XBiotech stock opened at $3.48 on Thursday. The stock has a fifty day moving average price of $3.40 and a two-hundred day moving average price of $5.50. XBiotech has a 52-week low of $2.94 and a 52-week high of $9.96. The firm has a market capitalization of $106.08 million, a P/E ratio of -3.22 and a beta of 1.25.

Institutional Inflows and Outflows

An institutional investor recently raised its position in XBiotech stock. Bank of America Corp DE boosted its stake in shares of XBiotech Inc. (NASDAQ:XBIT) by 42.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,888 shares of the biopharmaceutical company’s stock after acquiring an additional 5,887 shares during the quarter. Bank of America Corp DE owned 0.07% of XBiotech worth $79,000 as of its most recent SEC filing. Institutional investors own 55.70% of the company’s stock.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.